Pharmaniaga Berhad Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	2.1yrs
Board average tenure	less than a year

Recent management updates

Recent updates

Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate

Apr 19

Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price

Oct 03

Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?

Jul 19

Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?

Feb 18

Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital

Dec 10

Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts

Nov 24

We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings

Aug 27

Pharmaniaga Berhad (KLSE:PHARMA) Has A Somewhat Strained Balance Sheet

May 28

CEO

Pharmaniaga Berhad has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Norai'ni Binti Mohamed Ali	Chief Financial Officer	11.8yrs	no data	no data
Mohd Othman	Technical Director & Head of Manufacturing Operations	1.3yrs	no data	no data
Badarulhisam Rahman	Chief Scientific Officer	1.3yrs	no data	no data
Zulkifli Bin Jafar	Deputy CEO & Executive Director	2.1yrs	RM1.01m	no data
Wan Intan Wan Ismail	Director of Corporate Governance & Company Secretary	4.4yrs	no data	no data
Idham Ismail	Chief Investment Officer	1.8yrs	no data	no data
Un Gee Hau	Senior General Manager of Marketing	19.8yrs	no data	no data
Zainudin Ismail	Chief People Officer	1.1yrs	no data	no data
Noor Binti Abu Bakar	Head of Sustainability	no data	no data	no data
Syaruzaimi Yusof	Company Secretary	4.4yrs	no data	no data
Ahmad Bakar	President Director of PT Millennium Pharmacon International Tbk	3.8yrs	no data	no data
Piping Pratamadita	President Director of PT Errita Pharma	1.9yrs	no data	no data

2.1yrs

Average Tenure

52yo

Average Age

Experienced Management: PHARMA's management team is considered experienced (2.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Zulkifli Bin Jafar	Deputy CEO & Executive Director	less than a year	RM1.01m	no data
Yves Champey	Member of Board Advisory Panel	no data	no data	no data
Izaddeen Bin Daud	Non-Independent Non-Executive Chairman	3.1yrs	RM134.05k	no data
Mohd Bin Zahur Hussain	Independent Non Executive Director	less than a year	RM40.00k	no data
V. Navaratnam	Member of Board Advisory Panel	no data	no data	no data
Musa bin Mohamad	Chairman of Board Advisory Panel	no data	no data	no data
Piero Olliaro	Member of Board Advisory Panel	no data	no data	no data
Mohammad Bin Md Radzi	Non Independent Non Executive Director	less than a year	no data	no data
Sarah binti Abdul Samat	Independent & Non-Executive Director	2.7yrs	RM158.35k	no data
Ahmad Shahredzuan Mohd Shariff	Non Independent & Non Executive Director	1.2yrs	no data	no data
Abdul Bin Ahmad	Senior Independent & Non-Executive Director	3.4yrs	RM154.68k	no data
Faridah Binti Md Yusof	Independent Non Executive Director	less than a year	no data	no data

0.9yrs

Average Tenure

50yo

Average Age

Experienced Board: PHARMA's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.

Pharmaniaga Berhad Management

Management criteria checks 1/4

Key information

Recent management updates

High number of new directors

Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Member of Audit Committee

Pharmaniaga Berhad Announces the Retirement of Encik Mohamed Iqbal Abdul Rahman as Chief Operating Officer

Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Director, Effective March 1, 2024

Pharmaniaga Berhad Appoints Dato' Dr Faridah Aryani Binti Md Yusof, as Independent and Non Executive Director Effective March 1, 2024

Pharmaniaga Berhad Announces Resignation of Puan Dayana Rogayah Binti Omar as Non Independent and Non Executive Alternate Director

Recent updates

High number of new directors

Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Member of Audit Committee

Pharmaniaga Berhad Announces the Retirement of Encik Mohamed Iqbal Abdul Rahman as Chief Operating Officer

New major risk - Revenue and earnings growth

Full year 2023 earnings released: RM0.057 loss per share (vs RM0.46 loss in FY 2022)

Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Director, Effective March 1, 2024

Pharmaniaga Berhad Appoints Dato' Dr Faridah Aryani Binti Md Yusof, as Independent and Non Executive Director Effective March 1, 2024

Pharmaniaga Berhad Announces Resignation of Puan Dayana Rogayah Binti Omar as Non Independent and Non Executive Alternate Director

New minor risk - Share price stability

Third quarter 2023 earnings released: RM0.037 loss per share (vs RM0.007 profit in 3Q 2022)

Price target decreased by 19% to RM0.28

High number of new and inexperienced directors

Second quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 2Q 2022)

Pharmaniaga Berhad Announces Appointment of Encik Ahmad Shahredzuan Mohd Shariff as Non Independent and Non Executive Member of Risk Committee

New minor risk - Shareholder dilution

New minor risk - Market cap size

Pharmaniaga Berhad announced that it expects to receive MYR 44.20988 million in funding

Pharmaniaga Berhad Announces the Retirement of Dr Mary Jane Cardosa as Independent and Non Executive Member of Risk Committee

First quarter 2023 earnings released: EPS: RM0.002 (vs RM0.021 in 1Q 2022)

Pharmaniaga Berhad Announces the Resignation of Datuk Dr Azhar Ahmad as Independent and Non Executive Director

Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate

Full year 2022 earnings released: RM0.46 loss per share (vs RM0.13 profit in FY 2021)

Price target decreased by 33% to RM0.41

Pharmaniaga Berhad Announces Resignation of Najmil Faiz Mohamed Aris as Independent and Non Executive Member of Nomination and Remuneration Committee

Third quarter 2022 earnings released: EPS: RM0.007 (vs RM0.038 in 3Q 2021)

Pharmaniaga Berhad Declares Third Interim Dividend for the Third Quarter Ended 30 September 2022, payable on 22 February 2023

High number of new directors

Pharmaniaga Berhad (KLSE:PHARMA) entered into a Memorandum of Understanding to acquire JDMAS Commerce Sdn Bhd.

Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price

Consensus EPS estimates fall by 13%

Price target decreased to RM0.75

Second quarter 2022 earnings released: EPS: RM0.001 (vs RM0.01 in 2Q 2021)

Pharmaniaga Berhad Announces Second Interim Dividend for the Year Ended December 31, 2022, Payable on October 04, 2022

Pharmaniaga Berhad Appoints Mary Jane Cardosa as Independent and Non Executive Member of Risk Committee

Pharmaniaga Berhad Appoints Mary Jane Cardosa as Independent and Non Executive Director

Pharmaniaga Berhad Appoints Datuk Lim Thean Shiang as Independent and Non Executive Director

Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?

Price target decreased to RM0.87

Pharmaniaga Berhad Declares First Interim Dividend for the Financial Year Ending 31 December 2022, Payable on 06 July 2022

Pharmaniaga Berhad Appoints Abdul Razak Bin Ahmad as Independent and Non-Executive Member of Risk Committee

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Pharmaniaga Berhad, Annual General Meeting, Jun 13, 2022

High number of new and inexperienced directors

Upcoming dividend of RM0.05 per share

Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?

Pharmaniaga Berhad Declares Fourth Interim Dividend for the Financial Year Ending 31 December 2021, Payable on 05 April 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Pharmaniaga Berhad Announces Re-Designation of Encik Zulkifli Jafar, Independent Director as Executive Director

Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital

Consensus EPS estimates increase to RM0.09

Upcoming dividend of RM0.02 per share

Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts

Third quarter 2021 earnings released: EPS RM0.038 (vs RM0.001 in 3Q 2020)

Upcoming dividend of RM0.015 per share

We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings

Independent Non-Executive Director Zainal Shariff has left the company

Second quarter 2021 earnings released: EPS RM0.011 (vs RM0.008 in 2Q 2020)

Pharmaniaga Berhad (KLSE:PHARMA) Has A Somewhat Strained Balance Sheet

Investor sentiment improved over the past week

Upcoming dividend of RM0.04 per share

Pharmaniaga Berhad Announces First Interim Dividend for the Financial Year Ending December 31, 2021, Payable on July 6, 2021

First quarter 2021 earnings released: EPS RM0.088 (vs RM0.086 in 1Q 2020)

Investor sentiment improved over the past week

Independent Non Executive Director has left the company

Independent & Non Executive Director has left the company

Upcoming dividend of RM0.01 per share

Price target decreased to RM4.17

Pharmaniaga Berhad Announces Fourth Interim Dividend for the Financial Year December 31, 2020, Payable on March 31, 2021

Full year 2020 earnings released